Wenju Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7746867/publications.pdf

Version: 2024-02-01

687363 552781 46 803 13 26 citations h-index g-index papers 48 48 48 1371 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. Clinical Cancer Research, 2019, 25, 3896-3907.	7.0	104
2	Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Management and Research, 2018, Volume 10, 3569-3577.	1.9	100
3	Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell, 2017, 21, 747-760.e7.	11.1	68
4	Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. International Journal of Cancer, 2018, 143, 2271-2280.	5.1	62
5	Isolation and culture of hepatic stellate cells from mouse liver. Acta Biochimica Et Biophysica Sinica, 2014, 46, 291-298.	2.0	57
6	Gastrin and upper GI cancers. Current Opinion in Pharmacology, 2016, 31, 31-37.	3.5	52
7	Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis. Cell Stem Cell, 2020, 26, 739-754.e8.	11.1	33
8	Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. International Journal of Oncology, 2016, 48, 1628-1638.	3.3	32
9	Imaging Tiny Hepatic Tumor Xenografts via Endoglin-Targeted Paramagnetic/Optical Nanoprobe. ACS Applied Materials & Diterfaces, 2018, 10, 17047-17057.	8.0	30
10	Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation. Oncologist, 2020, 25, e1031-e1041.	3.7	28
11	Early activated hepatic stellate cell-derived paracrine molecules modulate acute liver injury and regeneration. Laboratory Investigation, 2017, 97, 318-328.	3.7	26
12	Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer. Annals of Surgery, 2016, 263, 434-439.	4.2	25
13	Short-term and long-term outcomes of robotic rectal surgeryâ€"from the real word data of 1145 consecutive cases in China. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 4079-4088.	2.4	15
14	A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. Journal of Translational Medicine, 2020, 18, 234.	4.4	14
15	CDKL1 promotes tumor proliferation and invasion in colorectal cancer. OncoTargets and Therapy, 2017, Volume 10, 1613-1624.	2.0	13
16	Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology, 2018, 2018, 1-14.	1.3	12
17	Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget, 2016, 7, 11380-11396.	1.8	12
18	Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases. Cancer Management and Research, 2018, Volume 10, 2871-2881.	1.9	11

#	Article	IF	Citations
19	High MICB expression as a biomarker for good prognosis of colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1405-1413.	2.5	11
20	HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 993-1002.	2.5	10
21	Comparison between robotic natural orifice specimen extraction surgery and traditional laparoscopic low anterior resection for middle and low rectal cancer: A propensity score matching analysis. Journal of Surgical Oncology, 2021, 124, 607-618.	1.7	9
22	CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer. American Journal of Cancer Research, 2019, 9, 2531-2543.	1.4	9
23	Activation of miR-500a-3p/CDK6 axis suppresses aerobic glycolysis and colorectal cancer progression. Journal of Translational Medicine, 2022, 20, 106.	4.4	9
24	Preoperative Hepatic and Regional Arterial Chemotherapy in Patients Who Underwent Curative Colorectal Cancer Resection. Annals of Surgery, 2021, 273, 1066-1075.	4.2	8
25	A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. American Journal of Cancer Research, 2015, 5, 674-88.	1.4	6
26	miRâ€'31â€'5pâ€' <i>DMD</i> axis as a novel biomarker for predicting the development and prognosis of sporadic earlyâ€'onset colorectal cancer. Oncology Letters, 2022, 23, 157.	1.8	6
27	The effect of non-curative endoscopic resection on cT1NOMO colorectal carcinoma patients who underwent additional surgery. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 2862-2869.	2.4	5
28	Robotic procedure versus open surgery for simultaneous resection of colorectal cancer with liver metastases: Short-term outcomes of a randomized controlled study Journal of Clinical Oncology, 2017, 35, 3575-3575.	1.6	5
29	Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. American Journal of Cancer Research, 2018, 8, 2337-2345.	1.4	5
30	A trinity technique for prevention of low rectal anastomotic leakage in the robotic era. European Journal of Surgical Oncology, 2020, 46, e47-e54.	1.0	4
31	Robotic vs. laparoscopic vs. open abdominoperineal resection for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial Journal of Clinical Oncology, 2017, 35, 3603-3603.	1.6	4
32	Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study. Frontiers in Oncology, 2022, 12, 838870.	2.8	4
33	Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases. Annals of Surgical Oncology, 2022, 29, 3593-3603.	1.5	3
34	<p>Predictive And Prognostic Value Of Hepatic Steatosis In Conversion Therapy For Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis</p> . Cancer Management and Research, 2019, Volume 11, 8315-8326.	1.9	2
35	Short-Term and Long-Term Outcomes in Mid and Low Rectal Cancer With Robotic Surgery. Frontiers in Oncology, 2021, 11, 603073.	2.8	2
36	The Combination of Neoadjuvant Therapy and Surgical Resection: A Safe and Effective Treatment for Rectal Gastrointestinal Stromal Tumors. Cancer Management and Research, 2021, Volume 13, 4671-4678.	1.9	2

#	Article	IF	CITATIONS
37	Anatomical Resection Improves Disease-Free Survival After Lung Metastasectomy of Colorectal Cancer. Cancer Management and Research, 2021, Volume 13, 9429-9437.	1.9	2
38	Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer. Journal of Cancer, 2021, 12, 4418-4423.	2.5	1
39	Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA Journal of Clinical Oncology, 2021, 39, 3123-3123.	1.6	1
40	Ratio of M2 tumor-associated macrophages as a better prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer Journal of Clinical Oncology, 2018, 36, e15582-e15582.	1.6	1
41	Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial Journal of Clinical Oncology, 2013, 31, 3610-3610.	1.6	0
42	Searching for predictive biomarkers on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases: An expended biomarker analysis based on BELIEF study Journal of Clinical Oncology, 2016, 34, e15079-e15079.	1.6	0
43	Tumor-associated macrophages as predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer Journal of Clinical Oncology, 2018, 36, 620-620.	1.6	0
44	Tumor purity as a prognostic factor in colon cancer Journal of Clinical Oncology, 2018, 36, e15646-e15646.	1.6	0
45	Comparison of HER2 overexpression with total <i>Her2</i> mutation on resistance of EGFR-targeted therapy in <i>Ras</i> wild-type mCRC patients Journal of Clinical Oncology, 2019, 37, 3594-3594.	1.6	0
46	Regorafenib in refractory metastatic colorectal cancer: A multi-center retrospective study Journal of Clinical Oncology, 2022, 40, e15580-e15580.	1.6	O